semaglutide radnor FullScopeMD | Semaglutide (ODT)

Moving forward, Felson wrote, "it will be important to obtain data on whether semaglutide is similarly effective in persons with osteoarthritis without obesity, as well as better data on whether GLP-1 receptor agonists prevent progressive structural deterioration of the joint in osteoarthritis." This double-blind STEP-9 study was conducted at 61 sites across 11 countries starting in October 2021

It remains an investigational compound, developed by Eli Lilly and Company, and is currently undergoing Phase 3 clinical trials

Because it is newer, there is less flexibility and less long-term data on optimal maintenance dosing

EXCEPTIONS Clonidine, guanfacine

It has shown promising results in clinical trials and offers a novel approach to weight management by influencing appetite and metabolism